Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Budesonide

FDA-approved product (aerosol, metered, nasal), marketed as Budesonide, Entocort Ec, Eohilia and 8 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
2 of 4

Chemical structure

Chemical structure of Budesonide
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Airway obstruction
  • Allergic rhinitis
  • Asthma
  • Chronic bronchitis
  • Chronic obstructive pulmonary disease
  • Crohn's disease
  • Emphysema
  • Esophageal disease
  • IGA glomerulonephritis
  • Nasal congestion
  • Rhinitis, Allergic, Perennial
  • Seasonal allergic rhinitis
  • Ulcerative colitis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Corticosteroids acting locally; Corticosteroids, potent (group iii); Corticosteroids; Glucocorticoids
FDA pharmacologic class
Corticosteroid FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli38.4% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae23.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis44.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Budesonide in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-9.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.4 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Budesonide with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Efficacy and Safety Study of Beclometasone/Formoterol Single Inhaler in Patients With COPD

    NCT00476099 · start 2006-12

    Registered record
    Registry ID
    NCT00476099
    Conditions
    Chronic Obstructive Pulmonary Disease
    Interventions
    Beclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI; Budesonide 200 µg plus formoterol 6 µg DPI; Formoterol 12 µg DPI
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-12
    Completion
    2008-11
    Enrolment
    828

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Obstructive Pulmonary Disease
    InterventionBeclomethasone 100 µg plus formoterol 6 µg (CHF1535) pMDI; Budesonide 200 µg plus formoterol 6 µg DPI; Formoterol 12 µg DPI
    PhasePhase 3
    Registry statusCompleted

  • Efficacy of SLITone in House Dust Mite Allergic Patients

    NCT00633919 · start 2006-07

    Registered record
    Registry ID
    NCT00633919
    Conditions
    Allergy
    Interventions
    SLITone(TM) Dermatophagoides mix; Placebo; Salbutamol inhaler; Budesonide/formoterol inhaler; Prednisone tablet; Desloratadine tablet; Budesonide nasal spray
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Completed
    Start
    2006-07
    Completion
    2009-02
    Enrolment
    124

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllergy
    InterventionSLITone(TM) Dermatophagoides mix; Placebo; Salbutamol inhaler; Budesonide/formoterol inhaler +3 more
    PhasePhase 2 / Phase 3
    Registry statusCompleted

  • A Comparison of Symbicort® Single Inhaler Therapy and Conventional Best Practice for the Treatment of Persistent Asthma

    NCT00628758 · start 2005-12

    Registered record
    Registry ID
    NCT00628758
    Conditions
    Asthma
    Interventions
    Symbicort TBH - Turbuhaler; beta-II-agonist, inhale steroid
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2005-12
    Completion
    2008-09
    Enrolment
    430

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAsthma
    InterventionSymbicort TBH - Turbuhaler; beta-II-agonist, inhale steroid
    PhasePhase 3
    Registry statusCompleted

  • Pathogenetic Mechanisms of Chronic Obstructive Pulmonary Diseases

    NCT01378039 · start 2004-06

    Registered record
    Registry ID
    NCT01378039
    Conditions
    COPD; Asthma
    Interventions
    comparison of treatment effect on different markers
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2004-06
    Completion
    2009-06
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCOPD; Asthma
    Interventioncomparison of treatment effect on different markers
    PhaseNot applicable
    Registry statusCompleted

  • Gemini Symbicort pMDI

    NCT00646516 · start 2003-10

    Registered record
    Registry ID
    NCT00646516
    Conditions
    Mild or Moderate Asthma
    Interventions
    budesonide/formoterol (Symbicort)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2003-10
    Completion
    2005-02
    Enrolment
    615

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMild or Moderate Asthma
    Interventionbudesonide/formoterol (Symbicort)
    PhasePhase 3
    Registry statusCompleted